NCT02345928 - A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

August 5, 2014

Primary Completion Date

March 16, 2017

Study Completion Date

March 16, 2017

Conditions

AsthmaAtopic DermatitisHealthy

Interventions

DRUG

Part 1: CNTO 7160

Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).

DRUG

Part 2 (Asthma): CNTO 7160

Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).

DRUG

Part 2 (Atopic Dermatitis): CNTO 7160

Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).

DRUG

Part 1 and Part 2: Placebo

Participants will receive single IV infusion of placebo matched to CNTO 7160.

Trial Locations (7)

Antwerp

Merksem

Berlin

Hamburg

Hanover

Kiel

Mönchengladbach

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY